Creager Cathy S DDS ,
-
Measles in the U.S.: Symptoms, Vaccine Guidance, and What Families Should Know in 2026
Measles cases have resurfaced in parts of the United States. Here’s what the CDC says about symptoms, vaccine protection, who is at risk, and when to seek care.
-
Can semaglutide help curb heavy drinking? Early trial hints yes
A small randomized trial suggests semaglutide may help reduce heavy drinking in adults with alcohol use disorder and obesity. The results are encouraging, but they are early and do not change standard treatment yet.
-
Aurora Bay Area Prices – PIPERACILLIN-TAZOBACTAM 3000 MG-375 MG PEDS IV SOLR (HOSP USE ONLY) is $13.2
At Aurora Bay Area, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10002800, regarding PIPERACILLIN-TAZOBACTAM 3000 MG-375 MG PEDS IV SOLR (HOSP USE ONLY), which is classified under revenue code 250 and associated with CPT code J2543, the designated fee stands at $13.2. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.
-
Hypoglycemia vs. Hyperglycemia: Key Differences Patients Should Understand
This article clearly explains the differences between hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) so patients and caregivers can respond quickly and confidently. It outlines typical symptoms—like shakiness, sweating, or confusion for lows, and excessive thirst, frequent urination, or fatigue for highs—common triggers, and immediate steps to take (fast-acting carbohydrates for lows; hydration, checking ketones, and using prescribed medications for highs). You’ll also find guidance on when to seek urgent care, how to prevent episodes through monitoring, meal planning, activity, and medication timing, and practical tips for everyday safety. The goal is to help you recognize problems early, treat them promptly, and reduce the risk of complications.
